Published in Hepatitis Weekly, September 30th, 2002
Deferiprone is used for ensuring thalessemia patients do not develop iron-induced organ damage as a result of the numerous iron transfusions they must receive. There have been conflicting reports concerning the role deferiprone plays in worsening fibrosis progression, according to Ian R. Wanless, an investigator in the Department of Laboratory and Pathobiology at the University of Toronto in Ontario, Canada. In one of the largest studies of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly